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plasia (OVH) are two relatively common oral precancerous
lesions. The malignant transformation rate is reported to be
18e47% (28% average) for OEL lesions and 3e17% for OVH
lesions. The high malignant transformation rates of OEL and
OVH lesions highlight the importance of early detection and
treatment of these two types of oral precancerous lesions.1
Surgical treatment of OEL and OVH lesions may be per-
formed either through conventional surgery, electro-
cauterization, laser ablation, or cryosurgery. However,
large OEL and OVH lesions treated by total surgical excision
frequently need skin grafting and often result in scar for-
mation.1 Photodynamic therapy (PDT) is another effective
treatment option for human oral precancerous lesions
because it can be used repeatedly without cumulative side
effects, results in little or no scar formation, has lower
invasiveness and ability to treat multifocal lesions, and canConflicts of interest: The authors have no conflicts of interest
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makers and bleeding tendency.1
One of the best strategies to prevent oral cancers is to
treat oral cancers at precancerous stages to avoid their
further malignant transformation. Our previous studies
used the light-emitting diode (LED) light and topical 5-
aminolevulinic acid-mediated PDT (topical ALA-PDT) to
treat 36 OVH lesions once a week. We found that all the 36
OVH lesions showed complete regression after an average
of 3.8 (range, 1e6) treatments of topical ALA-PDT.2 For
comparison, 40 OVH lesions were treated with topical ALA-
PDT using the 635-nm laser light once a week. We also
discovered that all the 40 OVH lesions exhibited complete
regression after an average of 3.6 (range, 1e6) PDT treat-
ments.3 In these two studies, OVH lesions with a clinical
appearance of a mass, the greatest diameter < 1.5 cm, a
pink color, epithelial dysplasia, or with the surface keratin
layer  40 mm needed significantly fewer treatments with
PDT to achieve a complete regression than OVH lesions with
a clinical appearance of a plaque or a combination type,
with the greatest diameter  1.5 cm, a white color, without
epithelial dysplasia, or with the surface keratin
layer > 40 mm, respectively.2,3 Although the mean treat-
ment number of PDT to achieve a complete regression for
the 40 (3.6  1.2) laser light-treated OVH lesions was lowerAssociation. All rights reserved.
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sions, no significant difference was found.2,3
Our group also used the topical ALA-PDTwith the 635-nm
LED light to treat 20 OEL lesions once a week. We found
that the 20 OEL lesions treated with topical ALA-PDT once a
week show complete response in 17 after an average of 3.7
(range, 2e7) treatments of ALA-PDT and partial response in
three.4 For comparison, 40 OEL lesions were treated with
topical ALA-PDT using the 635-nm laser light once a week.
Of the 40 OEL lesions, 38 showed complete response after
an average of 3.4 (range, 2e6) PDT treatments and two
show partial response.3 In these two studies, we also
discovered that the mean treatment number of PDT to
achieve a complete response for OEL lesions with the
greatest diameter < 1.5 cm or with the surface keratin
layer  30 mm was significantly lower than for OEL lesions
with the greatest diameter  1.5 cm or with the surface
keratin layer > 30 mm, respectively.3,4 Although the mean
treatment number of PDT to achieve a complete response
for the 38 (3.4  1.4) laser light-treated OEL lesions was
lower than that for the 17 (3.7  1.4) LED light-treated OEL
lesions, no significant difference was found.3,4
The efficacy of topical ALA-PDT can be enhanced by
pretreatment of methotrexate. Pretreatment of SCC4 cells
by 0.001 mg/L methotrexate for 72 hours results in a sig-
nificant increase in methotrexate-ALA-PDT-induced killing
of SCC4 cells.5 In addition, topical methotrexate-
pretreatment can increase intracellular protoporphyrin IX
production in hamster buccal pouch precancerous lesions
and significantly improves the outcomes of the precancer-
ous lesions treated with topical ALA-PDT.6 Chang and Yu7
used topical ALA-PDT and then cryogun cryotherapy to
treat a large OVH lesion at the same visit and achieved
complete regression of the lesion after six treatments of
combination therapy. Actually, cryogun cryotherapy can
also be used before topical ALA-PDT at the same visit to
facilitate the diffusion of ALA into the precancerous
epithelial cells and to improve the clinical outcome of
topical ALA-PDT.1,8
We conclude that topical ALA-PDT using either the LED
or laser light is a very effective treatment modality for OVHand OEL lesions. Therefore, topical ALA-PDT using either
the LED or laser light can serve as the first-line treatment of
choice for OVH and OEL lesions. When topical ALA-PDT is
combined with methotrexate pretreatment, its efficacy can
be augmented through upregulation of coproporphyrinogen
oxidase.5,6 Moreover, cryotherapy pretreatment can in-
crease the diffusion of ALA into precancerous epithelial
cells and in turn enhances the clinical outcomes of oral
precancers treated with topical ALA-PDT.1,8References
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